{"id":"W2913281659","doi":"10.1200/jco.2019.37.4_suppl.tps718","title":"Open-label phase II/III study of nivolumab plus standard of care versus standard of care for first-line treatment of metastatic colorectal cancer: Checkmate-9X8.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Nivolumab; Bevacizumab; Irinotecan; Colorectal cancer; Oncology; Internal medicine; Oxaliplatin; Immunotherapy; Progression-free survival; Phases of clinical research; Clinical trial; Cancer; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001849004,0.001699385,0.002373022,0.0005655769,0.0004314573,0.001426845,0.001471265,0.002134793,0.008460739],"category_scores_gemma":[0.001442787,0.000691496,0.001567473,0.0004082131,0.001268971,0.001248878,0.0003475955,0.004068352,0.001660643],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001633919,"about_ca_system_score_gemma":0.001724154,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001992689,"about_ca_topic_score_gemma":0.00486433,"domain_scores_codex":[0.9995807,0.0001926657,0.00001481937,0.00007992481,0.00004200258,0.00009004142],"domain_scores_gemma":[0.9988519,0.0002310175,0.0002078037,0.00008090738,0.0000819803,0.0005464663],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8829556,0.07295096,0.0009581063,0.0005698919,0.0007913263,0.00006479509,0.0001088705,0.001188106,0.008114328,0.0002079314,0.002788511,0.02930161],"study_design_scores_gemma":[0.6954167,0.2982132,0.002412501,0.00002690239,0.0002591138,0.00006223671,0.00003869137,0.001179444,0.001061797,0.0001667461,0.001142041,0.00002053418],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9835547,0.002744407,0.0008684769,0.0007418119,0.0006381202,0.006153119,0.00197809,0.0002346743,0.003086738],"genre_scores_gemma":[0.9803678,0.002088645,0.002548138,0.001602977,0.0003907031,0.004930195,0.002473989,0.00005385883,0.005543847],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008460739,"threshold_uncertainty_score":0.02830398,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1642373479300006,"score_gpt":0.5189681292614418,"score_spread":0.3547307813314412,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}